Fresenius SE & Co. KGaA · XETR:FRE

Fresenius SE & Co. KGaA — Shareholder Meeting (May 2024)

40 slides from Fresenius SE & Co. KGaA's shareholder meeting presentation, May 17, 2024

  1. Slide 1: Fresenius Annual General Meeting

    Fresenius Annual General Meeting Frankfurt am Main, May 17, 2024 Presentation of Michael Sen, CEO of the Management Board 17.05.2024 | Fresenius Annual General Meeting 2024

  2. Slide 2: Fresenius

    = Fresenius

  3. Slide 3: 17.05.2024 | Fresenius Annual General Meeting 2024

    17.05.2024 | Fresenius Annual General Meeting 2024

  4. Slide 4: Every fourth blood bag worldwide comes from Fresenius

    Every fourth blood bag worldwide comes from Fresenius 27 million blood bags sold in 2023 17.05.2024 | Fresenius Annual General Meeting 2024 4

  5. Slide 5: #FutureFresenius

    #FutureFresenius 17.05.2024 | Fresenius Annual General Meeting 2024 5

  6. Slide 6: Four phases to becoming the leading healthcare company

    #FutureFresenius Four phases to becoming the leading healthcare company REIMAGINE REJUVENATE REVITALIZE RESET 17.05.2024 | Fresenius Annual General Meeting 2024 6

  7. Slide 7: Four phases to becoming the leading healthcare company

    #FutureFresenius Four phases to becoming the leading healthcare company REIMAGINE REJUVENATE REVITALIZE RESET 17.05.2024 | Fresenius Annual General Meeting 2024 7

  8. Slide 8: Share price: continuous improvement since turnaround

    Share price: continuous improvement since turnaround 17.05.2024 | Fresenius Annual General Meeting 2024 8

  9. Slide 9: Raised outlook for 2024 fiscal year

    Raised outlook for 2024 fiscal year 4-7% 6 - 10 % Organic EBIT growth revenue growth before special items in constant currency 17.05.2024 | Fresenius Annual General Meeting 2024 9

  10. Slide 10: 17.05.2024 | Fresenius Annual General Meeting 2024

    17.05.2024 | Fresenius Annual General Meeting 2024 10

  11. Slide 11: Historic step through deconsolidation

    Historic step through deconsolidation For greater freedom and responsibility 17.05.2024 | Fresenius Annual General Meeting 2024

  12. Slide 12: Simplified structure, sharper focus

    Simplified structure, sharper focus 32 % stake Fresenius Kabi Fresenius Helios Pharma Biopharma Nutrition MedTech 17.05.2024 | Fresenius Annual General Meeting 2024 12

  13. Slide 13: 2023 fiscal year a success

    2023 fiscal year a success Revenue €22.3bn +6 %* EBIT €2.3bn +2 %** EBIT margin 10.1 % Operating cash flow €2.1bn +5 % * Organic growth ** EBIT growth rate in constant currency 17.05.2024 | Fresenius Annual General Meeting 2024 13

  14. Slide 14: Consistently good performance Fresenius Kabi and Fresenius Helios

    Consistently good performance Fresenius Kabi and Fresenius Helios Q1 23 Q2 23 Q3 23 FY 23 Revenue* +7 %** +7 %** +7 %** +7 %** Fresenius Kabi EBIT -4 % +1 % +2 % +3 % Revenue* +5 % +6 % +6 % +5 % Fresenius Helios EBIT +2 % +3 % +4 % +4 % Before special items; EBIT growth rates in constant currency *

  15. Slide 15: Growth on a broad basis: 2023 at Fresenius Kabi

    Growth on a broad basis 2023 fiscal year at Fresenius Kabi Fresenius Kabi Revenue* €8bn +7 %** Ambition level: 4 - 7 % EBIT €1.15bn +3 %*** 14.3 % Ambition level: 14 - 17 % EBIT margin * Organic growth ** Excluding the significant inflationary effects in Argentina *** EBIT growth rates in constant c

  16. Slide 16: Digitalization paying off: 2023 at Fresenius Helios

    Digitalization paying off 2023 fiscal year at Fresenius Helios Fresenius Helios Revenue* €12.3bn +5 % Ambition level: 3 - 5 % EBIT €1.2bn +4 %** 10.0 % Ambition level: 9 - 11 % EBIT margin * Organic growth ** EBIT growth rates in constant currency 17.05.2024 | Fresenius Annual General Meeting 2024 1

  17. Slide 17: On track to achieve ambitious savings targets

    On track to achieve ambitious savings targets Cost and efficiency program leading to greater competitiveness ~ €400 ~ €350 million ~ €280 million ~ €200 million million Old New Expected Actuals target target 2023 2025 17.05.2024 | Fresenius Annual General Meeting 2024 17

  18. Slide 18: Fresenius Kabi

    Fresenius Kabi 17.05.2024 | Fresenius Annual General Meeting 2024

  19. Slide 19: Fresenius Kabi

    Fresenius Kabi Innovative development and production platform. Strong network for biopharmaceuticals. 17.05.2024 | Fresenius Annual General Meeting 2024

  20. Slide 20: Fresenius Kabi Biopharma

    Fresenius Kabi Biopharma Cost-efficient and highly effective alternatives for treating cancer and autoimmune diseases. Excellent start with biosimilar Tyenne® in USA and EU. 17.05.2024 | Fresenius Annual General Meeting 2024

  21. Slide 21: Fresenius Helios

    Fresenius Helios 17.05.2024 | Fresenius Annual General Meeting 2024

  22. Slide 22: Fresenius Helios

    Fresenius Helios Modern technologies in daily clinical practice for optimized patient care. 20 DaVinci surgical robots in use at Helios hospitals in Germany. 17.05.2024 | Fresenius Annual General Meeting 2024

  23. Slide 23: Fresenius Helios

    Fresenius Helios Casiopea digital healthcare platform simplifies clinical processes. 6 million active users in Spain (approx. 12.5% of population). 17.05.2024 | Fresenius Annual General Meeting 2024

  24. Slide 24: 17.05.2024 | Fresenius Annual General Meeting 2024

    17.05.2024 | Fresenius Annual General Meeting 2024 24

  25. Slide 25: Robust and dynamic growth: global healthcare services market

    Robust and dynamic growth The global market for healthcare services ~ $8 ~ $10 trillion trillion market volume market volume in 2027 in 2023 Source: Projections for the International Healthcare Sector, 2023 (The Business Research Company) 17.05.2024 | Fresenius Annual General Meeting 2024 25

  26. Slide 26: Driver of the healthcare industry: technology

    Driver of the healthcare industry: technology 17.05.2024 | Fresenius Annual General Meeting 2024

  27. Slide 27: Artificial intelligence in healthcare

    Artificial intelligence in healthcare Market size in US dollars ~ $188 billion $200 billion $150 billion $100 billion ~ $21 billion $50 billion 2023 2030 Source: Artificial Intelligence (AI) in Healthcare Market Size Worldwide from 2021 to 2030 (Statista) 17.05.2024 | Fresenius Annual General Meetin

  28. Slide 28: Driver of the healthcare industry: data

    Driver of the healthcare industry: data 17.05.2024 | Fresenius Annual General Meeting 2024

  29. Slide 29: Digitalization of healthcare

    Digitalization of healthcare “Digitizing the patient healthcare journey offers a wide range of benefits and solutions to healthcare system challenges by enhancing efficiency, improving patient outcomes, 97% and increasing access to healthcare.” of health data World Economic Forum, Transforming Healt

  30. Slide 30: Driver of the healthcare industry: biomedical research

    Driver of the healthcare industry: biomedical research 17.05.2024 | Fresenius Annual General Meeting 2024

  31. Slide 31: Focus on people

    Focus on people 17.05.2024 | Fresenius Annual General Meeting 2024

  32. Slide 32: 3 platforms for profitable growth

    3 platforms for profitable growth (Bio)Pharma MedTech Care Provision 17.05.2024 | Fresenius Annual General Meeting 2024

  33. Slide 33: Market potential of the platforms: €1 trillion

    Market potential of the 3 platforms €1 trillion 17.05.2024 | Fresenius Annual General Meeting 2024 33

  34. Slide 34: The Fresenius ecosystem: a strong global network

    The Fresenius ecosystem A strong global network 17.05.2024 | Fresenius Annual General Meeting 2024 34

  35. Slide 35: Team Fresenius is growing

    Team Fresenius is growing +5,000 employees in 2023 6,700 apprentices and dual students 40 apprenticeships 30 dual study programs 17.05.2024 | Fresenius Annual General Meeting 2024

  36. Slide 36: ESG influences our actions

    ESG influences our actions On course for climate neutrality Climate -50 % neutral CO2 emissions -22 % since 2020 CO2 emissions since 2020 2020 2023 2030 2040 17.05.2024 | Fresenius Annual General Meeting 2024

  37. Slide 37: A leading global company

    A leading global company 80 countries 190,000+ colleagues 150 nationalities 17.05.2024 | Fresenius Annual General Meeting 2024 37

  38. Slide 38: Active for our patients worldwide

    Active for our patients worldwide 26 million patients 450 million lives touched 17.05.2024 | Fresenius Annual General Meeting 2024

  39. Slide 39: 17.05.2024 | Fresenius Annual General Meeting 2024

    17.05.2024 | Fresenius Annual General Meeting 2024 39

  40. Slide 40: Committed to Life

    COMMITTED TO LIFE 17.05.2024 | Fresenius Annual General Meeting 2024 40

Fresenius SE & Co. KGaA — Shareholder Meeting (May 2024) on 6ix